First Patient in BTKi Combination Cohort of azer-cel study
Filed with ASX · · 3 pages · English
Story so far
Earlier from Imugene
- Azer-cel Data from CAR T naive cohort in ASCO 2026 abstract
- Diamond Equity Research Releases Update Note on Imugene Limited (ASX: IMU)
- Prospectus
- $20M placement and SPP, convertible notes amended
- 100% and 80% ORRs in Subset Indications in azer-cel study
Later from Imugene
- Azer-cel Granted FDA Fast Track Designation for CLL and MZL
- First Complete Response in Concurrent BTKi azer-cel Cohort
- New Complete Response in the Concurrent BTKi azer-cel Cohort
- $11.1 Million Placement Completed to Advance azer-cel
- Third response in concurrent BTKi Cohort of azer-cel Trial
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene